Clinical Trial

Adjuvant Quisinostat in High-Risk Uveal Melanoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to see if giving participants quisinostat will prevent participants' uveal melanoma tumor from spreading. The researchers want to find out the effects that quisinostat has on participants' condition.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-10; most recent amendment 2026-06-16.
Status change: Not Yet Recruiting → Recruiting 2025-05-08
Trial Details
NCT Number NCT06932757
Lead Sponsor University of Miami
Collaborators: Viriom, Joseph and Florence Mandel Family Foundation
Conditions Uveal Melanoma
Enrollment 63 participants
Start Date 2025-05-27
Primary Completion 2030-05-27 (estimated)
Study Completion 2030-05-27 (estimated)
Updated on ClinicalTrials.gov 2026-06-18